[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Lippi et al., 2000 - Google Patents

Lipoprotein (a): from ancestral benefit to modern pathogen?

Lippi et al., 2000

View PDF
Document ID
17767897390670329221
Author
Lippi G
Guidi G
Publication year
Publication venue
Qjm

External Links

Snippet

We review current concepts regarding the genetic, structural and metabolic features of lipoprotein (a), a major inherited cardiovascular pathogen. Although lipoprotein (a) is almost completely confined to a subset of primates, the hedgehog produces a lipoprotein (a)‐like …
Continue reading at academic.oup.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Lippi et al. Lipoprotein (a): from ancestral benefit to modern pathogen?
Schmidt et al. Structure, function, and genetics of lipoprotein (a)
Ellis et al. The renaissance of lipoprotein (a): brave new world for preventive cardiology?
Ma et al. High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform.
Connelly et al. Hepatic lipase deficiency
Fox et al. Ceruloplasmin and cardiovascular disease
Kronenberg et al. Lipoprotein (a): resurrected by genetics
Chasman et al. Polymorphism in the apolipoprotein (a) gene, plasma lipoprotein (a), cardiovascular disease, and low-dose aspirin therapy
Morange et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study
Mbewu et al. Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis
Wehling-Henricks et al. Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy
Hajjar, MD et al. The role of lipoprotein (a) in atherogenesis and thrombosis
Loscalzo Lipoprotein (a). A unique risk factor for atherothrombotic disease.
Li et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp (a) in cultured human endothelial cells
McCormick Lipoprotein (a): biology and clinical importance
Zhang et al. Interaction of myeloperoxidase with vascular NAD (P) H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases
de la Peña-Dı́az et al. Lipoprotein Lp (a) and atherothrombotic disease
Marcovina et al. A critical evaluation of the role of Lp (a) in cardiovascular disease: can Lp (a) be useful in risk assessment?
Sankaranarayanan et al. Ionizing radiation and genetic risks: VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus
Utermann Lipoprotein (a): a genetic risk factor for premature coronary heart disease
Scanu et al. Learning about the structure and biology of human lipoprotein [a] through dissection by enzymes of the elastase family: facts and speculations
Zhu et al. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1
Nishihama et al. Association of gene polymorphisms with myocardial infarction in individuals with or without conventional coronary risk factors
Lawn How often has Lp (a) evolved?
Hoffmann et al. Apolipoprotein E1 Baden (Arg180→ Cys): A new apolipoprotein E variant associated with hypertriglyceridemia